Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronate in early stage breast cancer
NCT03664687Phase 4Completed
- Sponsor
- Ottawa Hospital Research Institute
- Start
- Oct 2018
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of zoledronate in breast cancer (2 arms), sponsored by Ottawa Hospital Research Institute. Primary endpoints: Multiple Site Activation at 12 months, Time to Activate Six Sites at 12 months and 2 more. Started Oct 2018; status: completed.
02
Drugs
zoledronate
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03664687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03664687.